Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

被引：397

作者：

Bittner, Vera A. ^{[1
]}

Szarek, Michael ^{[2
]}

Aylward, Philip E. ^{[3
,30
]}

Bhatt, Deepak L. ^{[4
,5
]}

Diaz, Rafael ^{[6
]}

Edelberg, Jay M. ^{[7
]}

Fras, Zlatko ^{[8
,9
,74
,75
]}

Goodman, Shaun G. ^{[10
,11
]}

Halvorsen, Sigrun ^{[12
,13
,64
]}

Hanotin, Corinne ^{[14
]}

Harrington, Robert A. ^{[15
]}

Jukema, J. Wouter ^{[16
]}

Loizeau, Virginie ^{[14
]}

Moriarty, Patrick M. ^{[17
,87
,1138
]}

Moryusef, Angele ^{[7
]}

Pordy, Robert ^{[18
]}

Roe, Matthew T. ^{[19
,20
]}

Sinnaeve, Peter ^{[21
,22
,32
]}

Tsimikas, Sotirios ^{[23
]}

Vogel, Robert ^{[24
,88
]}

White, Harvey D. ^{[25
]}

Zahger, Doron ^{[26
,52
]}

Zeiher, Andreas M. ^{[27
]}

Steg, Gabriel ^{[28
,29
]}

Schwartz, Gregory G. ^{[24
]}

Aylward, Philip E. ^{[3
,30
]}

Drexel, Heinz ^{[31
,173
]}

Sinnaeve, Peter ^{[21
,22
,32
]}

Dilic, Mirza ^{[33
]}

Lopes, Renato D. ^{[1
,96
,238
]}

Gotcheva, Nina N. ^{[34
,254
]}

Prieto, Juan-Carlos ^{[35
,299
]}

Yong, Huo ^{[36
]}

Lopez-Jaramillo, Patricio ^{[37
]}

Pecin, Ivan ^{[38
]}

Reiner, Zeljko ^{[39
]}

Ostadal, Petr ^{[40
,401
]}

Poulsen, Steen Hvitfeldt ^{[41
]}

Viigimaa, Margus ^{[42
]}

Nieminen, Markku S. ^{[43
]}

Danchin, Nicolas ^{[44
]}

Chumburidze, Vakhtang ^{[45
]}

Marx, Nikolaus ^{[46
,470
]}

Liberopoulos, Evangelos ^{[47
,493
]}

Montenegro Valdovinos, Pablo Carlos ^{[48
]}

Tse, Hung-Fat ^{[49
]}

Kiss, Robert Gabor ^{[50
,507
]}

Xavier, Denis ^{[51
]}

Zahger, Doron ^{[26
,52
]}

Valgimigli, Marco ^{[53
]}

机构：

[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL USA

[2] SUNY, Downstate Sch Publ Hlth, Brooklyn, NY USA

[3] Flinders Univ & Med Ctr, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Inst Cardiovasc Rosario, Estudios Cardiol Latinoamer, Rosario, Argentina

[7] Sanofi, Bridgewater, MA USA

[8] Univ Med Ctr Ljubljana, Prevent Cardiol Unit, Div Med, Dept Vasc Med, Ljubljana, Slovenia

[9] Univ Ljubljana, Med Fac, Ljubljana, Slovenia

[10] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada

[11] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[12] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway

[13] Univ Oslo, Oslo, Norway

[14] Sanofi, Paris, France

[15] Stanford Univ, Dept Med, Stanford Ctr Clin Res, Stanford, CA 94305 USA

[16] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands

[17] Univ Kansas, Med Ctr, Div Clin Pharmacol, Kansas City, KS 66103 USA

[18] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[19] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[20] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27706 USA

[21] Univ Hosp Leuven, Dept Cardiovasc Med, Leuven, Belgium

[22] Univ Leuven, Leuven, Belgium

[23] Univ Calif San Diego, Div Cardiovasc Med, La Jolla, CA 92093 USA

[24] Univ Colorado, Div Cardiol, Sch Med, Aurora, CO USA

[25] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand

[26] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Fac Hlth Sci, Beer Sheva, Israel

[27] Goethe Univ, Dept Med 3, Frankfurt, Germany

[28] Univ Paris, Hop Bichat, AP HP, FACT,INSERM,U1148, Paris, France

[29] Imperial Coll, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England

[30] Flinders Univ & Med Ctr, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[31] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[32] UZ Leuven, Leuven, Belgium

[33] Univ Clin Ctr Sarajevo, Sarajevo, Bosnia & Herceg

[34] MHAT Natl Cardiol Hosp EAD, Sofia, Bulgaria

[35] Hosp Clin Univ Chile, Santiago, Chile

[36] Peking Univ First Hosp, Beijing, Peoples R China

[37] Fdn Oftalmol Santander FOSCAL, Floridablanca, Colombia

[38] Univ Zagreb, Univ Hosp Ctr Zagreb, Zagreb Sch Med, Zagreb, Croatia

[39] Univ Zagreb, Univ Hosp Ctr Zagreb, Sch Med, Zagreb, Croatia

[40] Na Homolce Hosp, Prague, Czech Republic

[41] Aarhus Univ Hosp Skejby, Aarhus N, Denmark

[42] SA Pohja Eesti Reg Haigla, Tallinn, Estonia

[43] HUCH, Div Cardiol, Heart & Lung Ctr, Helsinki, Finland

[44] FACT, Hop Europeen Georges Pompidou, Paris, France

[45] Chapidze Emergency Cardiol Ctr, Tbilisi, Georgia

[46] Univ Klinikum Aachen, Aachen, Germany

[47] Univ Gen Hosp Ioannina, Ioannina, Greece

[48] Clin Privada, Unidad Diagnost Cardiol, Guatemala City, Guatemala

[49] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China

[50] Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 02期

关键词：

acute coronary syndromes; alirocumab; low-density lipoprotein cholesterol; major adverse cardiovascular events; proprotein convertase subtilisin/kexin type 9 inhibition; REDUCING LIPIDS; EFFICACY; DISEASE; SAFETY; CHOLESTEROL; NIACIN;

D O I：

10.1016/j.jacc.2019.10.057

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). OBJECTIVES A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C independently predicted major adverse cardiovascular events (MACE). METHODS One to 12 months after ACS, 18,924 patients on high-intensity statin therapy were randomized to alirocumab or placebo and followed for 2.8 years (median). Lipoprotein(a) was measured at randomization and 4 and 12 months thereafter. The primary MACE outcome was coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina. RESULTS Baseline lipoprotein(a) levels (median: 21.2 mg/dl; interquartile range [IQR]: 6.7 to 59.6 mg/dl) and LDL-C [corrected for cholesterol content in lipoprotein(a)] predicted MACE. Alirocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 to 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.78 to 0.93). Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics. A 1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.990 to 0.999; p = 0.0081). CONCLUSIONS Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS. Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402) (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

引用

页码：133 / 144

页数：12

共 50 条

[21] Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome
Cavallari, Ilaria
Cannon, Christopher P.
Braunwald, Eugene
Goodrich, Erica L.
Im, KyungAh
Lukas, Mary Ann
O'Donoghue, Michelle L.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2018, 25 (08) : 830 - 838
[22] Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
Sinnaeve, Peter R.
Schwartz, Gregory G.
Wojdyla, Daniel M.
Alings, Marco
Bhatt, Deepak L.
Bittner, Vera A.
Chiang, Chern-En
Flores, Roger M. Correa
Diaz, Rafael
Dorobantu, Maria
Goodman, Shaun G.
Jukema, J. Wouter
Kim, Yong-Un
Pordy, Robert
Roe, Matthew T.
Sy, Rody G.
Szarek, Michael
White, Harvey D.
Zeiher, Andreas M.
Steg, Ph Gabriel
EUROPEAN HEART JOURNAL, 2020, 41 (24) : 2248 - 2258
[23] Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
Geba, Gregory P.
Chen, Ruifeng
Talapatra, Kasturi
Brackin, Taylor
Mohammadi, Kusha A.
Pordy, Robert
Manvelian, Garen
Maron, David J.
Schwartz, Gregory G.
Szarek, Michael
Steg, Ph. Gabriel
Fazio, Sergio
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 20
[24] Acute Decline in Renal Function, Inflammation, and Cardiovascular Risk after an Acute Coronary Syndrome
Mielniczuk, Lisa M.
Pfeffer, Marc A.
Lewis, Eldrin F.
Blazing, Michael A.
de Lemos, James A.
Mohanavelu, Satishkumar
Rouleau, Jean
Fox, Keith
Pedersen, Terje R.
Califf, Robert M.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (11): : 1811 - 1817
[25] Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes
Moriarty, Patrick M.
Steg, Philippe Gabriel
McGinniss, Jennifer
Zeiher, Andreas M.
White, Harvey D.
Manvelian, Garen
Pordy, Robert
Loy, Megan
Jukema, J. Wouter
Harrington, Robert A.
V. Gray, Jessica
Gorby, Lauryn K.
Goodman, Shaun G.
Diaz, Rafael
Bittner, Vera A.
Bhatt, Deepak L.
Szarek, Michael
Schwartz, Gregory G.
ODYSSEY OUTCOMES Investigators
JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 747 - 756
[26] ASSESSMENT OF CARDIOVASCULAR RISK: EXAMINING THE RELATIONSHIP BETWEEN LIPOPROTEIN(A) ELEVATION AND RECURRENT ACUTE CORONARY SYNDROME
Olakunle, Oreoluwa E.
Pollock, Zoe
Trandel, Elizabeth
Fleurant, Marshall
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 3315 - 3315
[27] Effect of PCSK9 inhibition with alirocumab on lipoprotein(a) in patients with high risk of cardiovascular disease
Safdar, S.
Cramb, R.
Dawson, C.
ATHEROSCLEROSIS SUPPLEMENTS, 2017, 28 : E12 - E12
[28] Walking the tightrope: cardiovascular risk prediction in patients after acute coronary syndrome
Gallacher, Peter J.
Shah, Anoop S. V.
HEART, 2020, 106 (07) : 484 - 486
[29] Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES
Schwartz, G.
Szarek, M.
Li, Q. H.
Chiang, C. E.
Diaz, R.
Hagstrom, E.
Huo, Y.
Jukema, J. W.
Lecorps, G.
Moryusef, A.
Pordy, R.
White, H. D.
Yusoff, K.
Zeiher, A. M.
Steg, P. G.
EUROPEAN HEART JOURNAL, 2019, 40 : 682 - 682
[30] Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Goodman, Shaun G.
Aylward, Philip E.
Szarek, Michael
Chumburidze, Vakhtang
Bhatt, Deepak L.
Bittner, Vera A.
Diaz, Rafael
Edelberg, Jay M.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Kedev, Sasko
Letierce, Alexia
Moryusef, Angele
Pordy, Robert
Lopez, Gabriel Arturo Ramos
Roe, Matthew T.
Viigimaa, Margus
White, Harvey D.
Zeiher, Andreas M.
Steg, Ph Gabriel
Schwartz, Gregory G.
Aylward, Philip E.
Drexel, Heinz
Sinnaeve, Peter
Dilic, Mirza
Lopes, Renato D.
Gotcheva, Nina N.
Prieto, Juan-Carlos
Yong, Huo
Lopez-Jaramillo, Patricio
Pecin, Ivan
Reiner, Zeljko
Ostadal, Petr
Poulsen, Steen Hvitfeldt
Viigimaa, Margus
Nieminen, Markku S.
Danchin, Nicolas
Chumburidze, Vakhtang
Marx, Nikolaus
Liberopoulos, Evangelos
Montenegro Valdovinos, Pablo Carlos
Tse, Hung-Fat
Kiss, Robert Gabor
Xavier, Denis
Zahger, Doron
Valgimigli, Marco
Kimura, Takeshi
Kim, Hyo Soo
Kim, Sang-Hyun
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (09) : 1177 - 1186

← 1 2 3 4 5 →